Exscientia vs MedGenome

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Exscientia employs 100-500 people, while MedGenome has 200-500 employees.

Exscientia has raised more in total funding at $500M, compared to MedGenome's $50M — a gap of $450M.

Exscientia holds the higher Awaira Score at 72/100, compared to MedGenome's 63/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 9-point gap that reflects meaningful differences in scale or traction.

Exscientia was founded by Andrew Hopkins in 2012. MedGenome was founded by Sam Santhosh in 2013. Visit each company's profile on Awaira for a full founder biography.

Exscientia: Exscientia is an AI-driven drug design company that uses automated design-make-test-analyse cycles to generate drug candidates with the goal of reducing the time and cost of small molecule drug discovery. The Oxford-originated company builds generative chemistry models and automated laboratory robotics that together create a closed-loop system for molecular design, synthesis, and assay testing, producing candidates in months rather than the years required by conventional medicinal chemistry programmes.\n\nThe company went public on NASDAQ under the ticker EXAI, having raised over $500 million in combined public and private funding from investors including Bristol-Myers Squibb, Celgene, SoftBank, and GT Healthcare Capital Partners. Exscientia has clinical-stage programmes in oncology and neuropsychiatry and reports being the first company to advance AI-designed drug candidates into human clinical trials. The company has multiple pharma partnerships including agreements with Bristol-Myers Squibb, Sanofi, and Evotec that provide milestone and royalty revenue.\n\nExscientia competes in the AI drug design space against Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics, and Insilico Medicine. The company differentiates through its integrated automated laboratory approach, which combines computational design with physical synthesis and testing in a single workflow rather than treating AI design as a separate step before conventional chemistry. Its public market position and disclosed clinical programmes provide transparency benchmarks against which the broader AI drug discovery sector is measured by investors and pharmaceutical partners. MedGenome: MedGenome is a genomics and precision medicine company that combines next-generation sequencing with AI-powered data analysis to deliver clinical genomic testing for rare diseases, hereditary cancers, and pharmacogenomics. The company operates a NABL-accredited genomics laboratory and a bioinformatics platform that interprets variant data against proprietary South Asian population databases.\n\nThe company raised approximately $50M across Series B and C rounds from investors including Sequoia India and CDC Group, and serves hospitals, research institutions, and pharmaceutical companies across India and Southeast Asia. MedGenome has built one of the largest repositories of South Asian genomic data, which is clinically significant given that most reference genome databases are biased toward European populations.\n\nThe underrepresentation of South Asian genetic variation in global genomic databases creates both a clinical risk and a commercial opportunity. MedGenome's proprietary database of South Asian genomic variants and its AI-powered interpretation capabilities represent a durable competitive asset as personalized medicine adoption grows across the Indian healthcare system.

Exscientia was founded first in 2012, giving it 1 year of additional market experience. MedGenome was founded later in 2013. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Exscientia has approximately 100-500 employees, while MedGenome has approximately 200-500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Exscientia and MedGenome are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.